A detailed history of Opaleye Management Inc. transactions in Relmada Therapeutics, Inc. stock. As of the latest transaction made, Opaleye Management Inc. holds 480,000 shares of RLMD stock, worth $182,400. This represents 0.28% of its overall portfolio holdings.

Number of Shares
480,000
Previous 600,000 20.0%
Holding current value
$182,400
Previous $1.8 Million 13.61%
% of portfolio
0.28%
Previous 0.46%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$2.3 - $4.36 $276,000 - $523,200
-120,000 Reduced 20.0%
480,000 $1.56 Million
Q2 2024

Aug 14, 2024

SELL
$2.93 - $4.94 $465,870 - $785,460
-159,000 Reduced 20.95%
600,000 $1.8 Million
Q1 2024

May 15, 2024

SELL
$3.1 - $6.8 $365,800 - $802,400
-118,000 Reduced 13.45%
759,000 $3.53 Million
Q4 2023

Feb 14, 2024

BUY
$2.45 - $4.22 $2.08 Million - $3.57 Million
847,000 Added 2823.33%
877,000 $3.63 Million
Q3 2023

Nov 14, 2023

BUY
$2.48 - $3.79 $74,400 - $113,700
30,000 New
30,000 $90,000

Others Institutions Holding RLMD

About RELMADA THERAPEUTICS, INC.


  • Ticker RLMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,608,500
  • Market Cap $10.9M
  • Description
  • Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...
More about RLMD
Track This Portfolio

Track Opaleye Management Inc. Portfolio

Follow Opaleye Management Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Opaleye Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Opaleye Management Inc. with notifications on news.